Home > Rheumatology > ACR 2020 > Late-Breaking News > JAK inhibition as a treatment option for ankylosing spondylitis

JAK inhibition as a treatment option for ankylosing spondylitis

Presented By
Prof. Atul Deodhar, Oregon Health & Science University, USA
ACR 2020
Tofacitinib demonstrated very promising results for oral treatment of active ankylosing spondylitis in a phase 3 trial. New safety risks were not detected. Several types of immune cells playing a role in the pathogenesis of spondyloarthritis use JAK pathways [1]. Hence, not surprisingly, JAK inhibitors such as tofacitinib have already shown promising results in phase 2 trials for ankylosing spondylitis (AS) and therefore have potential to become a therapeutic option for this indication in the future [2,3]. The oral JAK inhibitor tofacitinib is now investigated in phase 3 for the treatment of AS [4]. This randomised, placebo-controlled, double-blind study included 269 adult patients with active AS, who met the modified New York criteria in centrally read radiographs. All patients had inadequate response or were intolerant to treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs). A primary analys...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on